Clinical Trials Logo

Hepatitis B clinical trials

View clinical trials related to Hepatitis B.

Filter by:

NCT ID: NCT00895596 Completed - Chronic Hepatitis B Clinical Trials

Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B

Start date: March 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to investigate the safety and the antiviral activity of ascending multiple oral doses of LB80380 for 12 weeks in adults with lamivudine-refractory chronic hepatitis B infection.

NCT ID: NCT00888407 Completed - Liver Cancer Clinical Trials

Community-based Hepatitis B Interventions for Hmong Adults

Start date: September 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to design an intervention to increase hepatitis B (HBV) screening among Hmong Americans.

NCT ID: NCT00886964 Completed - HIV Infections Clinical Trials

Hepatitis B Vaccination (HBV) in HIV Infected Children

Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is : - To evaluate prevalence of protective hepatitis B antibody comparing intradermal (ID) and intramuscular (IM) route in antiHbsAb negative HIV infected children treated with highly active antiretroviral therapy (HAART) - To revaccinate the HBV vaccine in the children who didn't have protective HBV Ab

NCT ID: NCT00883844 Completed - Chronic Hepatitis B Clinical Trials

PEG-IFN in HBV Patients With Incomplete Response to NA

PADD
Start date: April 2009
Phase: Phase 4
Study type: Interventional

Treatment with a nucleoside analogue and subsequent viral decline has shown to partially restore immune hyporesponsiveness in chronic hepatitis B patients. Recent pilot studies investigating whether the effect of lowering viral load with nucleoside analogue therapy prior to the initiation of peginterferon results in higher sustained off-treatment responses showed contradictory findings. The aim of this study is to investigate sustained off-treatment response to peginterferon alfa-2b in chronic HBeAg-positive hepatitis B patients who are pretreated with nucleos(t)ide analogues, thereby lowering viral load

NCT ID: NCT00881036 Completed - Hepatitis B Clinical Trials

Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients

Start date: August 2006
Phase: N/A
Study type: Observational

Individuals with resolved hepatitis B, characterized as hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody-positive, have latent hepatitis B virus (HBV) infection in their liver tissue. Cytotoxic chemotherapy and hematopoietic stem cell transplantation sometimes trigger the reactivation of latently infected HBV, resulting in de novo hepatitis B. Although de novo hepatitis B could cause acute liver failure or chronic hepatitis, an effective management strategy for de novo hepatitis B has not been well established. Risk factors and effective management for de novo hepatitis B will be clarified.

NCT ID: NCT00880477 Completed - Hepatitis B Clinical Trials

Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine

Start date: January 2001
Phase: Phase 3
Study type: Interventional

This study will assess the immunogenicity, safety and reactogenicity of GSK Biological's DTPa-HBV-IPV/ Hib vaccine as compared to GSK's DTPa-IPV/Hib vaccine co-administered with HBV according to a three-dose immunisation course and as a booster dose in infants born to hepatitis B antigen seronegative mothers and previously primed with a birth dose of GSK's HBV vaccine.

NCT ID: NCT00879827 Completed - Hepatitis B Clinical Trials

Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants

Start date: September 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the immune response and reactogenicity of GSK Biologicals' DTPa-HBV-IPV combined pentavalent vaccine and Hib tetanus conjugate vaccine, administered concomitantly as a three-dose primary vaccination course.

NCT ID: NCT00877760 Completed - Chronic Hepatitis B Clinical Trials

Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B

ARES
Start date: August 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate whether it is possible to augment the response of patients with HBeAg-positive chronic hepatitis B to entecavir by using a temporary peginterferon alpha-2a add-on strategy

NCT ID: NCT00877149 Completed - Clinical trials for Compensated Chronic Hepatitis B

Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B

Start date: March 2009
Phase: Phase 4
Study type: Interventional

The purpose of this trial is to provide data of absence of inflammation in patient liver histology after long-term telbivudine treatment and thus help investigators to make a comprehensive judgment on treatment discontinuation in selected patients

NCT ID: NCT00876148 Completed - Clinical trials for Hematological Malignancies

Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting

Start date: n/a
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.